HistoSonics develops a groundbreaking non-invasive ultrasound-based Histotripsy Platform to transform liver tumour treatment
The groundbreaking histotripsy therapy platform, developed by the US medical device company HistoSonics, Inc.(USA), uses focused ultrasound to liquefy and destroy targeted liver tumours under real-time image guidance, without the invasiveness or toxicity of traditional oncological treatments.